FDA approves new drug for advanced head and neck squamous cell carcinoma

Medical Xpress - latest medical and health news stories ·
Health & Medicine United Kingdom

The U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt of platinum-based chemotherapy and immunotherapy.

Read original article on Medical Xpress - latest medical and health news stories →